gracecast- asco lung 2020- the sindas trial - the addition of sbrt to a systemic egfr inhibitor tki
Published 3 years ago • 78 plays • Length 13:31Download video MP4
Download video MP3
Similar videos
-
12:58
egfr inhibitor therapy in second line
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
6:31
gracecast - lcvl - what is the best first line treatment for patients with advanced egfr mutation-po
-
29:24
gracecast-068_lung-cancer_sequist on acquired resistance to egfr
-
5:34
gracecastuc-038_lung_managing acq. resistance to egfr therapy (and probably crizotinib, too)
-
10:43
gracecast-007_lung-cancer_optimal treatment of unresectable locally advanced nsclc
-
21:23
immunotherapy for targeted therapies - what do we know helena yu, md
-
9:18
gracecast - treatment options for metastatic nsclc
-
10:39
gracecast - lcvl - can patients with an egfr mutation-positive advanced nsclc benefit from immunothe
-
6:14
gracecast-124_rad_refining radiation therapy for lc, pt 4: defining a role for sbrt
-
10:57
gracecast-033_lung-cancer_individualizing treatment for nsclc
-
10:16
overcoming resistance in egfr nsclc - lung cancer onctalk 2022
-
18:51
gracecast-140_lung_highlights in lung cancer, 2012: new options for egfr mutation-positive nsclc
-
9:49
gracecast-001_lung-cancer_first line chemo for advanced nscl
-
12:33
gracecast-025_lung-cancer_questions and trials for nsclc